Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management

NCT06959810 | Recruiting

• 1 other identifier: OEUVRE
• Study Type: interventional
• Target: 55
• Locations: 1 country
• Sites: 1

Brief Summary

Treatment for cancers of the pharyngolarynx is mutilating, with major consequences for patients' lives in terms of physical and functional after-effects. The psycho-social consequences are also significant, notably the metamorphosis of identity linked to the disease and its treatment, which alters the patient's self-image. Initial feedback from patients who have been able to benefit from adapted oncoesthetics (OEA) is overwhelmingly positive. This study will assess the feasibility of oncoesthetics and describe any obstacles.

Conditions

Oncology; Aerodigestive Tract Cancer; Suportive Care

Keywords

Oncology (Organ: Upper Aero Digestive Tract); Supportive Oncology; Organization of care

Outcome Measures

Primary Outcomes (1)

• Evaluate, in patients treated for cancer of the upper aerodigestive tract, the impact of early treatment with Adapted Onco-Esthetics

  Evaluation of the proportion of patients reporting no worsening of self-image representation, as measured by the BIS body image scale.

  At each session (first , second and third). An interval of one to 4 weeks between 2 sessions is permitted

Study Arms (1)

Three sessions of Adapted Onco-Esthetics

EXPERIMENTAL

Patients will received three sessions of Adapted Onco-Esthetics

Other: Adapted Onco-Esthetics sessions

Interventions

Adapted Onco-Esthetics sessions OTHER

Patient will received three sessions of Adapted Onco-Esthetics

Three sessions of Adapted Onco-Esthetics

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient aged 18 or over
• Neoplastic location: oropharynx, oral cavity, hypopharynx, larynx, nasal cavity, salivary glands, cavum, sinus.
• Patient due to start oncological treatment (recurrence authorized)
• Patient fluent in French.
• Affiliation with a social security scheme
• Signature of informed consent prior to any specific procedure linked to the study
• Treatment with curative intent

You may not qualify if:

• Breast-feeding or pregnant patient
• Any associated medical or psychological condition that could compromise the patient's ability to participate in the study
• Patient deprived of liberty, under guardianship, or subject to a legal protection measure or unable to express their consent.
• Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons.

Sponsors & Collaborators

• Centre Francois Baclesse: lead
• Fondation de France: collaborator
• GIRCI NO: collaborator

Study Sites (1)

Centre Francois Baclesse

Caen, France

RECRUITING

MeSH Terms

Conditions

Neoplasms

Central Study Contacts

Marielle RENOU, Care Manager

CONTACT

33231455050; m.renou@baclesse.unicancer.fr

Francois GERNIER, Care Manager

CONTACT

33231455050; f.gernier@baclesse.unicancer.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 23, 2025
• First Posted: May 7, 2025
• Study Start: October 24, 2025
• Primary Completion (Estimated): September 15, 2027
• Study Completion (Estimated): September 15, 2028
• Last Updated: March 12, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)